Literature DB >> 23968359

Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors.

Yasumi Furui1, Masahiro Satake, Yuji Hoshi, Shigeharu Uchida, Ko Suzuki, Kenji Tadokoro.   

Abstract

BACKGROUND: The current prevalence of cytomegalovirus (CMV) in Japan and the risk of CMV transfusion transmission are unknown in the era of seronegative leukoreduced blood components. STUDY DESIGN AND METHODS: We measured CMV-specific immunoglobulin (Ig)M and IgG in 2400 samples of whole blood collected from 12 groups of blood donors categorized by sex and age at 10-year intervals from their teens to their 60s. We also tested for CMV DNA using polymerase chain reaction in the cellular fractions of all samples.
RESULTS: We found that 76.6% of blood donors were CMV seropositive. The seroprevalences among donors in their 20s and 30s were 58.3 and 73.3%, respectively. We detected CMV DNA in the cellular fraction of 4.3% of samples from donors in their 60s and in 1.0% of samples from donors younger than 60 years. None of the 562 seronegative samples was DNA positive. Furthermore, 14% of DNA-positive samples also contained DNA in the plasma fraction, and two of five such samples were derived from donors in their 60s. Leukoreduced plasma components derived from donations with CMV DNA in plasma samples also contained a relevant amount of CMV DNA.
CONCLUSION: The seroprevalence of CMV among Japanese blood donors of child-bearing age has not changed over the past 15 years. Latent CMV becomes reactivated more frequently among elderly donors than among younger donors. A proportion of them have free CMV DNA in their plasma fraction, which could not be diminished by leukoreduction. The risk of transfusion-transmitted CMV infection in blood with plasma CMV DNA should be determined.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23968359     DOI: 10.1111/trf.12390

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  28 in total

1.  Carotid atherosclerosis, cytomegalovirus infection, and cognitive decline in the very old: a community-based prospective cohort study.

Authors:  Midori Kawasaki; Yasumichi Arai; Michiyo Takayama; Takumi Hirata; Midori Takayama; Yukiko Abe; Hidehito Niimura; Masaru Mimura; Toru Takebayashi; Nobuyoshi Hirose
Journal:  Age (Dordr)       Date:  2016-02-17

2.  Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit.

Authors:  O Coşkun; E Yazici; F Şahiner; A Karakaş; S Kiliç; M Tekin; C Artuk; L Yamanel; B A Beşirbellioğlu
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-19       Impact factor: 0.840

3.  Pancytopenia secondary to cytomegalovirus reactivation.

Authors:  Justin Ruey Tse; Gan Xon Ng
Journal:  BMJ Case Rep       Date:  2014-01-13

4.  Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.

Authors:  Sophie Voruz; Peter Gowland; Claudia Eyer; Nadja Widmer; Mélanie Abonnenc; Michel Prudent; Stavroula Masouridi-Levrat; Michel A Duchosal; Christoph Niederhauser
Journal:  Blood Transfus       Date:  2020-02-28       Impact factor: 3.443

5.  Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.

Authors:  Ghady Haidar; Michael Boeckh; Nina Singh
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

6.  Clinical significance of cytomegalovirus (CMV) pp65 antigenemia in the prediction of CMV infection during immunosuppressive therapy for rheumatic disease.

Authors:  Kensuke Suga; Aya Nishiwaki; Takayuki Nakamura; Shin-Ichiro Kagami
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

7.  Characterization of Baboon Cytomegalovirus Infection in Healthy Adult Baboons (Papio anubis).

Authors:  Erin L Willis; Taylor L Stevens; Gary L White; Dianne Mcfarlane
Journal:  Comp Med       Date:  2019-01-31       Impact factor: 0.982

8.  Latency for cytomegalovirus impacts T cell ageing significantly in elderly end-stage renal disease patients.

Authors:  L Huang; A W Langerak; C C Baan; N H R Litjens; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2016-08-19       Impact factor: 4.330

9.  Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.

Authors:  Takehiko Mori; Yoshinobu Kanda; Katsuto Takenaka; Shinichiro Okamoto; Jun Kato; Junya Kanda; Goichi Yoshimoto; Hisashi Gondo; Sayaka Doi; Masaki Inaba; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2016-10-28       Impact factor: 2.319

10.  Retinal and Choroidal Pathologies in Aged BALB/c Mice Following Systemic Neonatal Murine Cytomegalovirus Infection.

Authors:  Jinxian Xu; Xinglou Liu; Xinyan Zhang; Brendan Marshall; Zheng Dong; Sylvia B Smith; Diego G Espinosa-Heidmann; Ming Zhang
Journal:  Am J Pathol       Date:  2021-06-28       Impact factor: 5.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.